Acquired by Viatris in Jan 2023
Company logo

OYST - Oyster Point Pharma, Inc.

NASDAQ -> Healthcare -> Biotechnology
Princeton, United States
Type: Equity

OYST price evolution
OYST
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Current assets
Cash $68.8 $104.94 $143.43 $193.43
Short term investments
Net receivables $13.18 $10.92 $5.74 $6.66
Inventory $6.96 $6.64 $4.09 $6.09
Total current assets $97.71 $132.72 $167.35 $215.25
Long term investments $0.89 $0.89 $0.89 $0.89
Property, plant & equipment $4.92 $5.2 $5.26 $5.4
Goodwill & intangible assets
Total noncurrent assets $11.49 $11.22 $9.37 $7.37
Total investments $0.89 $0.89 $0.89 $0.89
Total assets $109.2 $143.94 $176.72 $222.62
Current liabilities
Accounts payable $4.14 $4.72 $2.6 $6.5
Deferred revenue
Short long term debt $0.69 $0.72 $0.71 $0.8
Total current liabilities $29.2 $31.13 $23.03 $28.8
Long term debt $94.03 $93.42 $92.64 $91.93
Total noncurrent liabilities $102.21 $102.03 $97.7 $94.28
Total debt $94.72 $94.14 $93.36 $92.73
Total liabilities $131.4 $133.16 $120.73 $123.08
Shareholders' equity
Retained earnings -$389.99 -$353.24 -$303.3 -$255.41
Other shareholder equity
Total shareholder equity -$22.2 $10.78 $55.99 $99.54
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Current assets
Cash $193.43 $192.65 $139.2 $5.23
Short term investments
Net receivables $6.66
Inventory $6.09
Total current assets $215.25 $196.37 $142.18 $5.62
Long term investments $0.89
Property, plant & equipment $5.4 $1.48 $0.98 $0.07
Goodwill & intangible assets
Total noncurrent assets $7.37 $1.54 $1.03 $0.09
Total investments $0.89
Total assets $222.62 $197.91 $143.21 $5.7
Current liabilities
Accounts payable $6.5 $2.28 $0.5 $0.46
Deferred revenue
Short long term debt $0.8 $0.42 $0.3 $0.06
Total current liabilities $28.8 $10.98 $5.4 $0.94
Long term debt $91.93 $0.27 $0.51 $0.01
Total noncurrent liabilities $94.28 $0.27 $0.51 $0.01
Total debt $92.73 $0.69 $0.81 $0.06
Total liabilities $123.08 $11.25 $5.91 $0.95
Shareholders' equity
Retained earnings -$255.41 -$154.75 -$84.23 -$38.52
Other shareholder equity
Total shareholder equity $99.54 $186.66 $137.3 -$38.24
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Revenue
Total revenue $5.59 $4.69 $2.7 $6.6
Cost of revenue $1.35 $1.31 $0.34 $1.52
Gross Profit $4.24 $3.38 $2.37 $5.07
Operating activities
Research & development $3.91 $4.66 $4.68 $5.46
Selling, general & administrative $34.24 $42.11 $39.9 $38.55
Total operating expenses $38.16 $46.77 $44.58 $44.01
Operating income -$33.91 -$43.39 -$42.21 -$38.94
Income from continuing operations
EBIT -$33.25 -$46.79 -$44.83 -$39.45
Income tax expense
Interest expense $3.5 $3.16 $3.07 $2.61
Net income
Net income -$36.75 -$49.94 -$47.89 -$42.06
Income (for common shares) -$36.75 -$49.94 -$47.89 -$42.06
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Revenue
Total revenue $24.54
Cost of revenue $1.52
Gross Profit $23.01
Operating activities
Research & development $24.23 $39.81 $33.63 $13.76
Selling, general & administrative $95.44 $31.18 $13.67 $2.98
Total operating expenses $119.67 $70.99 $47.3 $16.74
Operating income -$96.66 -$70.99 -$47.3 -$16.74
Income from continuing operations
EBIT -$96.92 -$70.52 -$45.71 -$16.5
Income tax expense
Interest expense $3.73
Net income
Net income -$100.66 -$70.52 -$45.71 -$16.5
Income (for common shares) -$100.66 -$70.52 -$45.71 -$16.5
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Net income -$36.75 -$49.94 -$47.89 -$42.06
Operating activities
Depreciation $0.28 $0.36 $0.33 $0.22
Business acquisitions & disposals
Stock-based compensation $3.77 $4.18 $4.36 $3.1
Total cash flows from operations -$35.97 -$38.83 -$49.7 -$41.48
Investing activities
Capital expenditures -$0.12 -$0.09 -$0.23
Investments
Total cash flows from investing -$0.12 -$0.09 -$0.23
Financing activities
Dividends paid
Sale and purchase of stock $0 $0.54 $0.08 $0.98
Net borrowings -$0.17 -$0.08 -$0.21 $49.93
Total cash flows from financing -$0.17 $0.46 -$0.22 $50.92
Effect of exchange rate
Change in cash and equivalents -$36.14 -$38.49 -$50.01 $9.21
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net income -$100.66 -$70.52 -$45.71 -$16.5
Operating activities
Depreciation $0.68 $0.46 $0.02
Business acquisitions & disposals
Stock-based compensation $11.95 $6.97 $3.27 $0.15
Total cash flows from operations -$89.37 -$58.4 -$40.81 -$17.08
Investing activities
Capital expenditures -$1.49 -$0.7 -$0.2
Investments
Total cash flows from investing -$1.49 -$0.7 -$0.2
Financing activities
Dividends paid
Sale and purchase of stock $1.59 $112.91 $82.13
Net borrowings $90.08
Total cash flows from financing $91.64 $112.55 $174.99
Effect of exchange rate
Change in cash and equivalents $0.79 $53.45 $133.97 -$17.08
Fundamentals
Market cap N/A
Enterprise value N/A
Shares outstanding 26.83M
Revenue $19.58M
EBITDA -$163.13M
EBIT -$164.32M
Net Income -$176.65M
Revenue Q/Q -68.84%
Revenue Y/Y 9.15%
P/E ratio 0.00
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio 0.00
Book/Share -0.83
Cash/Share 2.56
EPS -$6.58
ROA -108.29%
ROE -490.33%
Debt/Equity 1.24
Net debt/EBITDA -0.38
Current ratio 3.35
Quick ratio 3.11